Fulgent Genetics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 months.
- Its last 3 Sell calls were followed by a 11% average decline over the next quarter.
- Recent price momentum is +2.4% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 7.3% of float.
- Analyst tilt is Hold.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 02:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth F
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | -19.5% | Better than 2% |
| Free cash flow CAGR (3Y) | -64.3% | Better than 2% |
Profitability D+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 40.6% | Better than 49% |
| Operating margin | -28.2% | Better than 11% |
| Net margin | -18.8% | Better than 13% |
| Return on equity | -5.4% | Better than 23% |
| Return on invested capital | -7.8% | Better than 19% |
Momentum B+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 21.2% | Better than 97% |
| 6-month return | 41.0% | Better than 93% |
| 12-month return (ex latest month) | -33.0% | Better than 8% |
| Distance below 52-week high | 22.3% | Better than 56% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 6.5x | Better than 90% |
| Debt to assets | 0.6% | Better than 95% |
| Interest coverage | -932.7x | Better than 2% |
| Free cash flow / net income | 163.7% | Better than 69% |
Analyst View N/A
What the Street thinks: share of Buy ratings and upside to the average target.
Not enough data to grade this factor.
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 24.78
- Open
- 24.50
- Day range
- 23.88 - 24.79
- Avg price
- 24.16
- Volume
- 322.99K
- Turnover
- 7.80M
- Turnover ratei
- 1.89%
- Volume ratioi
- 1.09
- Amplitudei
- 3.67%
- 52-week rangei
- 13.46 - 31.04
Valuation
- P/Ei
- -12.24
- P/E (TTM)i
- -7.78
- P/Bi
- 0.68
- EPSi
- -1.97
- Book value / shi
- 35.45
- Net profit
- -55.04M
- Net assets
- 990.49M
Share structure
- Market cap
- 673.89M
- Float capi
- 413.02M
- Shares out
- 27.94M
- Float sharesi
- 17.12M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2016-09-29
22.3% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-2.78M net over the window
Short interest
- Shares short
- 2.02M
- % of floati
- 7.33%
- Days to coveri
- 7.81
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Fulgent Genetics (FLGT)?
Fulgent Genetics last traded at 24.12. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Fulgent Genetics's market cap?
About 673.89M.
What is the P/E ratio of Fulgent Genetics?
The trailing twelve-month P/E is -7.78. The Valuation tab shows it against the stock's own five-year range.
Does Fulgent Genetics pay a dividend?
Fulgent Genetics does not currently pay a regular dividend.
Is Fulgent Genetics a buy according to analysts?
The consensus of 1 analysts is a Hold rating, with an average 12-month price target of 19.00, which implies 21.2% downside from the current price. This is not investment advice.
What is Fulgent Genetics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Fulgent Genetics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Fulgent Genetics discussion 0 comments